Old drug, new hope: atovaquone tested against tough ovarian cancer
NCT ID NCT05998135
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether atovaquone, a drug currently used to treat certain infections, can help control platinum-resistant ovarian cancer. The study enrolls 28 patients whose cancer has progressed within six months of their last platinum-based chemotherapy. Participants will take atovaquone by mouth and undergo regular scans and biopsies to see if the drug slows tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atovaquone
What this could lead to
If it works, this could offer a new treatment option for ovarian cancer that has stopped responding to standard platinum chemotherapy.
What could go wrong
This is a small, early-phase trial with only 28 participants. The drug is being tested for a new purpose, so it may not work against cancer, and side effects are not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••